News & Media

Take a closer look at what we’re doing across Teva in Canada and worldwide

Teva Canada Limited, headquartered in Toronto, and Teva Canada Innovation, headquartered in Montréal, are part of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug maker. We’re proud to have been part of Canadian healthcare for more than 50 years, to market more than 400 medications across the country and to employ more than 1,000 Canadians.

If you’re looking for information about our company, please contact Public Affairs at Teva Canada Limited at Public.Affairs@tevacanada.com.

COVID-19: We'll get through this together

As the COVID-19 situation evolves globally, we are striving to provide an uninterrupted supply of medicines to the 200 million patients that we serve around the world. The global emergency surrounding COVID-19 is disrupting the family, work and social lives of many people around the world. At Teva, we’re working hard to keep the flow of medicines going to patients and healthcare systems. Thousands of colleagues have adapted the way they operate in order to continue performing essential work on our production lines, warehouses and distribution networks. See how Teva is working to keep medicines moving.

Watch video COVID-19: We'll get through this together

Latest news

Read the latest Teva news

Teva Canada Charts a New Prescription for Care - New initiatives planned to spark dialogue on future...

Teva Canada Charts a New Prescription for Care - New initiatives planned to spark dialogue on future healthcare delivery

New public drug plan reimbursement for AJOVY®

New public drug plan reimbursement for AJOVY®

Important Information – Voluntary Nationwide Recall - Novo-Gesic Forte® 500 mg (Acetaminophen) Table...

Important Information – Voluntary Nationwide Recall - Novo-Gesic Forte® 500 mg (Acetaminophen) Tablets

Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions

Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions

Teva Canada Welcomes Efforts to Address Critical Drug Supply in the Federal Budget

Teva Canada Welcomes Efforts to Address Critical Drug Supply in the Federal Budget

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatme...

Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma

Teva Canada announces product availability of AJOVY™

Teva Canada announces product availability of AJOVY™

Featured stories